Compare GSBD & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBD | OLMA |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 943.9M | 949.3M |
| IPO Year | 2013 | 2020 |
| Metric | GSBD | OLMA |
|---|---|---|
| Price | $7.69 | $7.01 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $8.63 | ★ $35.50 |
| AVG Volume (30 Days) | 814.9K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | ★ 17.18% | N/A |
| EPS Growth | ★ 87.27 | 15.00 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $156.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.70 | $6.24 |
| 52 Week High | $10.38 | $36.26 |
| Indicator | GSBD | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 22.22 | 43.95 |
| Support Level | N/A | $6.47 |
| Resistance Level | $9.08 | $7.61 |
| Average True Range (ATR) | 0.22 | 0.60 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 0.36 | 16.77 |
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.